NEW YORK (GenomeWeb News) – Ohio State University today announced it has licensed to Microlin Bio almost 100 issued and pending microRNA patents for the potential development of cancer diagnostics and treatments.

Microlin also licensed a novel nucleic acid delivery technology from OSU to deliver new therapies to cancer patients. The new therapies would be based on the miRNA patents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.